{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:25:49Z","timestamp":1793298349873,"version":"4.5.0"},"reference-count":27,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2011,10,1]],"date-time":"2011-10-01T00:00:00Z","timestamp":1317427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2011,10]]},"DOI":"10.1016\/j.atherosclerosis.2011.07.007","type":"journal-article","created":{"date-parts":[[2011,7,24]],"date-time":"2011-07-24T15:49:17Z","timestamp":1311522557000},"page":"451-456","source":"Crossref","is-referenced-by-count":55,"title":["Mechanisms of statin-induced myalgia assessed by physiogenomic associations"],"prefix":"10.1016","volume":"218","author":[{"given":"Gualberto","family":"Rua\u00f1o","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Windemuth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan H.B.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Kane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary J.","family":"Malloy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clive R.","family":"Pullinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Kocherla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kali","family":"Bogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce R.","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore R.","family":"Holford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankur","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard L.","family":"Seip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0005","unstructured":"Findlay S. The statin drugs. Prescription and price trends October 2005 to December 2006 and potential cost savings to Medicare from increased use of lower cost statins. Consumer Reports 2007."},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0010","unstructured":"Statins The World Market, 2009\u20132024. 3-3-2009. London, UK: Visiongain, Ltd."},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0015","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.amjcard.2006.01.066","article-title":"What the statin trials have taught us","volume":"98","author":"Waters","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0020","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1001\/jama.289.13.1681","article-title":"Statin-associated myopathy","volume":"289","author":"Thompson","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0025","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients\u2014the PRIMO study","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0035","doi-asserted-by":"crossref","first-page":"865","DOI":"10.2217\/14622416.6.8.865","article-title":"Physiogenomic analysis links serum creatine kinase activities during statin therapy to vascular smooth muscle homeostasis","volume":"6","author":"Rua\u00f1o","year":"2005","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0040","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/mus.20871","article-title":"Physiogenomic association of statin-related myalgia to serotonin receptors","volume":"36","author":"Rua\u00f1o","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0045","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy\u2014a genomewide study","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0050","series-title":"The biomedical engineering handbook","article-title":"Integrating Systems Engineering and Nanotechnology for Personalized Medicine","author":"Rua\u00f1o","year":"2005"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0055","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1097\/BOR.0b013e328314b7b4","article-title":"Genetic predisposition to statin myopathy","volume":"20","author":"Vladutiu","year":"2008","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0060","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1042\/BJ20040261","article-title":"Isolation and functional expression of human COQ2, a gene encoding a polyprenyl transferase involved in the synthesis of CoQ","volume":"382","author":"Forsgren","year":"2004","journal-title":"Biochem J"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0065","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2007.02.049","article-title":"The role of coenzyme Q10 in statin-associated myopathy: a systematic review","volume":"49","author":"Marcoff","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0070","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/1476-511X-6-7","article-title":"Genetic determinants of statin intolerance","volume":"6","author":"Oh","year":"2007","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0075","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1080\/01926230590908213","article-title":"Statin-induced muscle necrosis in the rat: distribution, development, and fibre selectivity","volume":"33","author":"Westwood","year":"2005","journal-title":"Toxicol Pathol"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0080","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0085","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0090","first-page":"258","article-title":"Statin myopathies: pathophysiologic and clinical perspectives","volume":"24","author":"Baker","year":"2001","journal-title":"Clin Invest Med"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0095","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1046\/j.1471-4159.1997.68031142.x","article-title":"an immunosuppressive drug, induces programmed cell death in rat C6 glioma cells by a mechanism that involves the AP-1 transcription factor","volume":"68","author":"Mosieniak","year":"1997","journal-title":"J Neurochem"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0100","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/path.2018","article-title":"Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia","volume":"210","author":"Draeger","year":"2006","journal-title":"J Pathol"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0105","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1002\/ajmg.a.32987","article-title":"Highly unstable sequence interruptions of the CTG repeat in the myotonic dystrophy gene","volume":"149A","author":"Musova","year":"2009","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0110","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1086\/514346","article-title":"Mendelian inheritance in man and its online version, OMIM","volume":"80","author":"McKusick","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0115","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1016\/j.jacc.2009.04.053","article-title":"The SLCO1B1*5 genetic variant is associated with statin-induced side effects","volume":"54","author":"Voora","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0120","doi-asserted-by":"crossref","first-page":"150","DOI":"10.2174\/1875692110806030150","article-title":"The pathway less traveled: moving from candidate genes to candidate pathways in the analysis of genome-wide data from large scale pharmacogenetic association studies","volume":"6","author":"Wilke","year":"2008","journal-title":"Curr Pharmacogenomics Person Med"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0125","series-title":"Pharmacogenomic testing in current clinical practice: implementation in the clinical laboratory","first-page":"155","article-title":"Genotype-guided statin therapy","author":"Seip","year":"2010"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0130","doi-asserted-by":"crossref","first-page":"613","DOI":"10.2217\/pgs.10.68","article-title":"Pharmacogenomics\u201410 years of progress: a cardiovascular perspective","volume":"11","author":"Winkelmann","year":"2010","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.atherosclerosis.2011.07.007_bib0135","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1161\/01.str.0000034125.94759.41","article-title":"ACC\/AHA\/NHLBI clinical advisory on the use and safety of statins","volume":"33","author":"Pasternak","year":"2002","journal-title":"Stroke"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011005867?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915011005867?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T09:55:00Z","timestamp":1543658100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915011005867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,10]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,10]]}},"alternative-id":["S0021915011005867"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.07.007","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2011,10]]}}}